Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 4Phase 1 4Phase 3 2Phase NA 1

Status

Recruiting 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 81Neoplasms 75Colorectal Neoplasms 65Neoplasm Metastasis 64Leukemia, Myeloid, Acute 62Prostatic Neoplasms 59Recurrence 53Pancreatic Neoplasms 51Ovarian Neoplasms 50Multiple Myeloma 50Triple Negative Breast Neoplasms 36Lung Neoplasms 36Melanoma 35Squamous Cell Carcinoma of Head and Neck 33Lymphoma, Non-Hodgkin 33Glioblastoma 31Carcinoma, Renal Cell 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Endometrial Neoplasms 28Carcinoma, Hepatocellular 28Stomach Neoplasms 26Small Cell Lung Carcinoma 26Leukemia, Lymphocytic, Chronic, B-Cell 26Myelodysplastic Syndromes 24Lymphoma, Follicular 24Lymphoma, B-Cell 24Sarcoma 23

Interventions

Docetaxel 2olaparib 1gedatolisib 1fludrocortisone acetate 1enzalutamide 1darolutamide 1cabazitaxel 1abiraterone 1Prednisone 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms, Castration-Resistant × 90 days × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06863272 2026-05-15

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04868604 2026-05-06

SECuRE

Clarity Pharmaceuticals Ltd

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT07258407 2026-03-16

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

T.O.A.D. Oncology SA

Phase 1/2 Recruiting
180 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡